Ftse Mib
38.273,35
0,12%
DAX
22.750,67
0,63%
S&P 500
5.614,56
-2,70%
NASDAQ
17.468,32
-4,00%
Bitcoin
80.948,41
3,15%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cadrenal Therapeutics Inc (CVKD) Cadrenal Therapeutics Inc (CVKD) Notizie

Cadrenal Therapeutics Inc

CVKD
15,42
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 09:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
04/3/202514:05EDGAR2Form 8-K - Current report
12/2/202519:05EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
07/2/202522:09EDGAR2Form 8-K - Current report
06/2/202515:00BWCadrenal Therapeutics Announces Chief Medical Officer..
05/2/202515:00BWCadrenal Therapeutics to Present at BIO CEO & Investor..
03/2/202523:12EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/1/202514:44BWCadrenal Therapeutics to Participate in the Lytham Partners..
31/12/202414:00BWCadrenal Therapeutics Provides 2024 Year-End Company Update,..
23/12/202422:44EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/12/202423:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/12/202415:00BWCadrenal Therapeutics Gears Up for the 43rd Annual J.P...
25/11/202422:53EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
25/11/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
19/11/202415:00PRNUSCadrenal Therapeutics Named Anticoagulation Therapy Company..
14/11/202422:05EDGAR2Form S-3 - Registration statement under Securities Act of..
12/11/202415:00PRNUSCADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN..
07/11/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202415:10EDGAR2Form 8-K - Current report
07/11/202415:00PRNUSCADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE..
04/11/202422:41EDGAR2Form 8-K - Current report
04/11/202415:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/11/202401:00PRNUSCadrenal Therapeutics Announces Exercise of Warrants for..
24/10/202415:10EDGAR2Form 8-K - Current report
24/10/202415:00PRNUSCadrenal Therapeutics Raises $5.1 Million via At-The-Market..
23/10/202415:00PRNUSCADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF..
04/10/202422:15EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
25/9/202422:05EDGAR2Form 8-K - Current report
23/9/202422:15PRNUSCadrenal Therapeutics to Participate in Lytham Partners Fall..
05/9/202422:59EDGAR2Form 8-K - Current report
22/8/202415:00PRNUSCadrenal Therapeutics Announces Upcoming Type-B FDA Meeting..
20/8/202415:00PRNUSPublished Findings Highlight Tecarfarin's Potential and..
20/8/202412:03EDGAR2Form 8-K - Current report
16/8/202412:03EDGAR2Form 8-K - Current report
14/8/202415:00PRNUSCadrenal Therapeutics to Present at Upcoming Investor..
08/8/202422:05EDGAR2Form 8-K - Current report
07/8/202422:05PRNUSCadrenal Therapeutics Provides Second Quarter 2024 Corporate..
07/8/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/8/202415:10EDGAR2Form 8-K - Current report
06/8/202415:00PRNUSCadrenal Therapeutics and Abbott Initiate Collaborative..
31/7/202422:05EDGAR2Form 8-K - Current report
12/6/202422:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/6/202423:25EDGAR2Form DEF 14A - Other definitive proxy statements
03/6/202415:00PRNUSCadrenal Therapeutics Highlights Presentation of New Trial..
29/5/202423:27EDGAR2Form PRE 14A - Other preliminary proxy statements
23/5/202415:00PRNUSCadrenal Therapeutics to Participate in the Lytham Partners..
09/5/202415:00PRNUSCadrenal Therapeutics Provides First Quarter 2024 Corporate..
09/5/202412:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/4/202422:30PRNUSCadrenal Therapeutics to Participate in Noble Capital..
09/4/202415:00PRNUSCadrenal Therapeutics Receives FDA Orphan Drug Designation..
11/3/202414:15EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 15,42

La tua Cronologia

NASDAQ
CVKD
Cadrenal Therapeutics
BOV
COGN3
COGNA ON
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci